Corrigendum to: Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized study
Mol Genet Metab
.
2023 Nov;140(3):107645.
doi: 10.1016/j.ymgme.2023.107645.
Epub 2023 Aug 3.
Authors
Joseph Muenzer
1
,
Barbara K Burton
2
,
Paul Harmatz
3
,
Luis González Gutiérrez-Solana
4
,
Matilde Ruiz-Garcia
5
,
Simon A Jones
6
,
Nathalie Guffon
7
,
Michal Inbar-Feigenberg
8
,
Drago Bratkovic
9
,
Michael Hale
10
,
Yuna Wu
11
,
Karen S Yee
12
,
David A H Whiteman
11
,
David Alexanderian
13
;
HGT-HIT-094 Study Group
Affiliations
1
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: muenzer@med.unc.edu.
2
Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Chicago, IL, USA.
3
UCSF Benioff Children's Hospital Oakland, Oakland, CA, USA.
4
Infant Jesus Children's Hospital, Madrid, Spain.
5
National Institute of Pediatrics, Mexico City, Mexico.
6
St Mary's Hospital, Manchester University NHS Foundation Trust, University of Manchester, Manchester, UK.
7
Reference Center for Inherited Metabolic Diseases, Hospices Civils de Lyon, Lyon, France.
8
University of Toronto, Toronto, ON, Canada; The Hospital for Sick Children, Toronto, ON, Canada.
9
Women's and Children's Hospital, North Adelaide, SA, Australia.
10
Takeda Development Center Americas, Inc., Cambridge, MA, USA; Hale Scientific Statistics, LLC, Beaverton, OR, USA.
11
Takeda Development Center Americas, Inc., Lexington, MA, USA.
12
Takeda Development Center Americas, Inc., Cambridge, MA, USA.
13
Takeda Development Center Americas, Inc., Lexington, MA, USA; Affinia Therapeutics, Inc., Waltham, MA, USA.
PMID:
37541906
DOI:
10.1016/j.ymgme.2023.107645
No abstract available
Publication types
Published Erratum